RE:RE:Article from Bloomberg of note
qwerty22 wrote: Egrifta doesn't impact subcutaneous fat.
“We evaluated the association of visceral-to-subcutaneous fat ratio (VSR) with nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis degree based on noninvasive serum fibrosis markers in the general population with NAFLD.
High VSR values predicted increased NAFLD risk and advanced fibrosis risk with NAFLD, and the predictive value of VSR for indeterminate to high risk of advanced fibrosis was higher in obese subjects than in nonobese subjects.”
As for NAFLD visceral fat is the concern as for diabetes, heat disease etc. again the article published today the issue isn’t subconscious fat so the whole idea of these weight loss meds is to better over all health rather than looking slim!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090310/